It is recommended that elderly patients (up to the age of 75 years) be included in randomized trials of chronic hepatitis C virus infection treatment.During the past decade, our knowledge of the pathogenesis, clinical course, and treatment of chronic hepatitis C virus (HCV) infection has increased tremendously. Search for other works by this author on: Chronic, long-term infection can result in liver damage, cirrhosis, and/or cancer of the liver.Chronic hep C infections are often asymptomatic. Clinical outcomes after transfusion-associated hepatitis CImpact of aging on the development of hepatocellular carcinoma in patients with hepatitis C virus infection in JapanDiagnosis, management, and treatment of hepatitis C. American Association for the Study of Liver DiseasesSurveillance for hepatocellular carcinoma in elderly Italian patients with cirrhosis: effects on cancer staging and patient survivalRates and risk factors of liver fibrosis progression in patients with chronic hepatitis CInterferon therapy for patients more than 60 years of age with chronic hepatitis CClinical significance of serum hepatitis C virus titers in patients with chronic type C hepatitisAdvancing donor liver age and rapid fibrosis progression following transplantation for hepatitis CFibrosis progression after liver transplantation in patients with recurrent hepatitis CIncreased fibrotic response in the ageing liver [abstract 570]Hepatitis C in 2410 patients 65 years or older: a severe and neglected curable disease [abstract 549]?Hepatitis C virus infection and related chronic liver disease in a resident elderly population: the Silea StudyLong-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: a National Heart, Lung, and Blood Institute collaborative studyAssessment of fatigue in patients with chronic hepatitis C using the Fatigue Impact ScaleHepatitis C and cognitive impairment in a cohort of patients with mild liver diseaseReplicative senescence of CD8 T cells: effect on human ageingMarked increase with age of type I cytokines within memory and effector/cytotoxic CD8Age-associated increased interleukin-6 gene expression, late-life diseases, and frailtyRebetol (Ribavirin, USP) capsules product informationFibroTest-FibroSURE: towards a universal biomarker of liver fibrosis?Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis CFIBROSpect II: a potential noninvasive test to assess hepatic fibrosisBiochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon α-2b and ribavirinAn algorithm for the grading of activity in chronic hepatitis C: the METAVIR Cooperative Study GroupInfluence of age, sex, and degree of liver fibrosis on the association between serum alanine aminotransferase levels and liver inflammation in patients with chronic hepatitis CPeginterferon α-2b plus ribavirin compared with interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trialPeginterferon α-2a plus ribavirin for chronic hepatitis C virus infectionAmantadine and interferon in the combined treatment of hepatitis C virus in elderly patientsEfficacy of interferon treatment (IFN) in elderly patients with chronic hepatitis CInterferon therapy for aged patients with chronic hepatitis C: improved survival in patients exhibiting a biochemical responseAntiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survivalElderly patients are at greater risk of cytopenia during antiviral therapy for hepatitis C [abstract 48]Single-dose pharmacokinetics and tolerability of pegylated interferon-α2b in young and elderly healthy subjectsCharacterization of pegylated (40 kDa) interferon α-2A (PEGASYS) in the elderly [abstract 755]Peginterferon α-2a: a review of approved and investigational usesHepatitis in nursing homes: incidence and management strategiesIncidence and clinical course of major depression in patients with chronic hepatitis type C undergoing interferon-α therapy: a prospective studyGeriatric renal function: estimating glomerular filtration in an ambulatory elderly populationFactors contributing to ribavirin dose reduction due to anemia during interferon α2b and ribavirin combination therapy for chronic hepatitis CEnd-of-treatment (EOT) response in therapy-naive patients treated for chronic hepatitis C with viramidine in combination with pegylated interferon α-2a [abstract 519]Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C© 2005 by the Infectious Diseases Society of America
During the past decade, our knowledge of the pathogenesis, clinical course, and treatment of chronic hepatitis C virus (HCV) infection has increased tremendously. The hepatitis C virus (HCV) spreads through contaminated blood.Until recently, hepatitis C treatment required weekly injections and oral medications that many HCV-infected people couldn't take because of other health problems or unacceptable side effects.That's changing.